Hepatitis C, interferon alfa, and depression

Hepatology

Volumn 31, Issue 6, 2000, Pages 1207-1211

  Zdilar, Darko ^a   Franco Bronson, Kathleen ^a   Buchler, Nancy ^a   Locala, Joseph A ^a   Younossi, Zobair M ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ANTIVIRUS AGENT; CITALOPRAM; FLUVOXAMINE; INTERFERON; MIRTAZAPINE; NEFAZODONE; PAROXETINE; RIBAVIRIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ANTICHOLINERGIC EFFECT; DEPRESSION; DRUG INDUCED DISEASE; ELECTROCONVULSIVE THERAPY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MENTAL DISEASE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; VIRUS HEPATITIS;

EID: 0034110583     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2000.7880     Document Type: Review

References (14)

1. Sarbah AS, Younossi ZM. Hepatitis C. An update on the silent epidemic. J Clin Gastroenterol 2000;30:125-143.
2. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-562.
3. Zeuzem S, Schmidt JM, Lee J-H, Ruster B, Roth WK. Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo. HEPATOLOGY 1996;23:366-371.
4. Bell J, Batey RG, Farell GC, Crewe EB, Cunningham AL, Byth K. Hepatitis C virus in intravenous drug users. Med J Aust 1990;153:274-276.
5. Fingerhood MI, Jasinski DR, Sullivan JT. Prevalence of hepatitis C in a chemically dependent population. Arch Intern Med 1993;153:2025-2030.
6. Woodfield DG, Harness M, Rix-Trott K, Tsuda F, Okamoto H, Mayumi M. Identification and genotyping of hepatitis C virus in injectable and oral drug users in New Zealand. Aust N Z J Med 1994;24:47-50.
7. Fisher DG, Fenaughty AM, Paschane AA, Paschane DM, Cagle HH, Orr SM. Hepatitis C virus infection among Alaskan drug users. Am J Public Health 1997;87:1722-1724.
8. Younossi ZM, McHutchison J. Serologic tests for HCV infection. Viral Hepatitis Reviews 1996;2:161-173.
9. Cividini A, Pistorio A, Regazzetti A, Cerino A, Tinelli C, Mancuso A, Ribola M, et al. Hepatitis C virus infection among institutionalised psychiatric patients: a regression analysis of indicators of risk. J Hepatol 1997;27:455-463.
10. Chang TT, Lin H, Yen YS, Wu HL. Hepatitis B and hepatitis C among institutionalized psychiatric patients in Taiwan. J Med Virol 1993;40:170-173.
11. Yates WR, Gleason O. Hepatitis C and depression. Depress Anxiety 1998;7:188-193.
12. Taruschio G, Santarini F, Sica G, Dragoni C, Migliorini S, Andreone P, Cursaro C, et al. Psychiatric disorders in hepatitis C virus related chronic liver disease [Abstract]. Gastroenterology 1996;110:A1342.
13. Hunt CM, Dominitz JA, Bute BP, Waters B, Blasi U, Williams DM. Effect of interferon-α treatment of chronic hepatitis C on health-related quality of life. Dig Dis Sci 1997;42:2482-2486.
14. Lee DH, Jamal H, Regenstein FG, Perrillo RP. Morbidity of chronic hepatitis C as seen in a tertiary care medical center. Dig Dis Sci 1997;42:186-191.